Skip to main content

Fluconazole Side Effects

Medically reviewed by Last updated on Feb 8, 2024.

Applies to fluconazole: oral powder for suspension, oral tablet. Other dosage forms:

Serious side effects of Fluconazole

Along with its needed effects, fluconazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking fluconazole:


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking fluconazole:

Symptoms of overdose

Other side effects of Fluconazole

Some side effects of fluconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to fluconazole: intravenous solution, oral powder for reconstitution, oral tablet.


This drug was generally well tolerated. Changes in renal and hematological function test results and hepatic abnormalities reported during therapy with this and comparative agents in some patients, primarily those with serious underlying diseases (e.g., AIDS, cancer); clinical significance and relationship to therapy unclear.

During clinical trials of single-dose therapy, side effects possibly related to therapy were reported in 26% of patients using this drug and 16% of patients using active comparative agents. The most common side effects reported in patients receiving a single 150 mg dose of this drug for vaginitis were headache, nausea, and abdominal pain. Most side effects were of mild to moderate severity.

During clinical trials of multiple-dose therapy, side effects were reported in 16% of patients. Therapy discontinuation occurred in 1.5% and 1.3% of patients due to adverse clinical events and laboratory test abnormalities, respectively. Clinical side effects were reported more often in HIV-infected patients than in non-HIV-infected patients (21% versus 13%), but the patterns in both groups were similar.[Ref]

Nervous system

Rare cases of seizures have been reported, but a causal relationship was difficult to establish, since some of these patients had cryptococcal meningitis or severe underlying disease. Nonetheless, at least 1 case of seizure following a 100 mg oral dose has been reported.

Seizures, dizziness, paresthesia, somnolence, tremor, and vertigo have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Headache (up to 13%)

Uncommon (0.1% to 1%): Seizures, dizziness, paresthesia, somnolence, vertigo, visual field defect, taste perversion, hyperkinesia, hypertonia

Rare (less than 0.1%): Tremor

Frequency not reported: Dysesthesias[Ref]


Dry mouth, dyspepsia, and vomiting have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Nausea, abdominal pain, diarrhea, vomiting

Common (1% to 10%): Dyspepsia

Uncommon (0.1% to 1%): Constipation, flatulence, loose stools, dry mouth

Frequency not reported: General abdominal discomfort[Ref]


Very common (10% or more): Increased ALT, increased AST

Uncommon (0.1% to 1%): Serum transaminase elevations, cholestasis, jaundice, increased bilirubin

Rare (less than 0.1%): Serious hepatic reactions, hepatic toxicity (including fatalities), hepatic failure, hepatocellular necrosis, hepatitis, hepatocellular damage

Frequency not reported: Hepatic reactions (ranging from mild transient transaminase elevations to clinical hepatitis, fulminant hepatic failure [including fatalities]), transient hepatic reactions (including hepatitis, jaundice), elevated liver function tests (transient and asymptomatic), cholestatic jaundice, fatal hepatic necrosis, increased plasma levels of hepatic enzymes[Ref]

Fatal hepatic reactions have occurred primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications. One reported patient with AIDS experienced acute hepatic necrosis and hepatic failure about 3 weeks after starting this drug.

Transient hepatic reactions have been reported in patients with no other identifiable risk factors. Liver function returned to baseline after stopping this drug.

Serum transaminase elevations (greater than 8 times the upper limit of normal [8 x ULN]; about 1%) and statistically significant increases in AST have been reported. Serum transaminase elevations have been reported primarily in patients with serious underlying medical conditions (primarily AIDS or malignancy) and often taking multiple concomitant medications, including agents known to be hepatotoxic.

Transaminase elevations greater than 2 to 3 x ULN have also been reported.

Cholestasis, hepatocellular damage, and hepatocellular necrosis have also been reported during postmarketing experience.[Ref]


Very common (10% or more): Rash

Common (1% to 10%): Maculopapular erythema

Uncommon (0.1% to 1%): Pruritus, genital pruritus, erythematous rash, dry skin, abnormal skin odor, urticaria, herpes simplex, drug eruption, increased sweating

Rare (less than 0.1%): Angioedema, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), alopecia, acute generalized exanthematous pustulosis, exfoliative dermatitis

Frequency not reported: Reversible alopecia, exfoliative skin disorders (including fatalities)[Ref]

Reversible alopecia has been associated with long-term (2 months or longer) therapy.

In patients with serious underlying diseases (primarily AIDS and malignancy), exfoliative skin disorders have resulted in a fatal outcome.

Acute generalized exanthematous pustulosis, drug eruption, increased sweating, exfoliative skin disorders (including Stevens-Johnson syndrome, toxic epidermal necrolysis), and alopecia have also been reported during postmarketing experience.[Ref]


Hypercholesterolemia, hypertriglyceridemia, and hypokalemia have also been reported during postmarketing experience.[Ref]

Very common (10% or more): Increased blood alkaline phosphatase

Uncommon (0.1% to 1%): Hypokalemia, anorexia, decreased appetite

Rare (less than 0.1%): Hypercholesterolemia, hypertriglyceridemia[Ref]


Rare (less than 0.1%): Anaphylactic reaction, anaphylaxis

Frequency not reported: Hypersensitivity reactions (including generalized edema, stridor, hypotension, exfoliative dermatitis, ulcerative eruptions), fixed drug eruption

Postmarketing reports: Anaphylaxis (including angioedema, face edema, pruritus)[Ref]

Rare cases of exfoliative dermatitis and ulcerative eruptions consistent with Stevens-Johnson syndrome have been reported in association with hypersensitivity reactions.

A 52-year-old female experienced a fixed drug eruption (FDE) when administered a single 400 mg oral dose for extensive pityriasis versicolor. Within 12 hours, she noticed 3 oval, painful, eroded, pigmented patches over her trunk with diameters of 3 to 4 cm and erythematous halos. A clinical diagnosis of FDE due to drug therapy was made. The FDE was confirmed when the patient was rechallenged with a 25 mg oral dose.[Ref]


Rare (less than 0.1%): QT prolongation, torsade de pointes

Frequency not reported: Prolongation of the QT interval on the ECG, palpitations, complex ventricular arrhythmia[Ref]

Most reports of QT interval prolongation and torsades de pointes involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications that may have been contributory.

An 11-year-old male with neurofibromatosis-1 presented to the hospital in septic shock secondary to a perforated gastric volvulus. After initial stabilization, the patient underwent total gastrectomy and multiple peritoneal lavages. Culture of peritoneal fluid showed infection with Candida albicans. Therapy was started with fluconazole 150 mg IV every 12 hours. After starting this drug, the patient developed QT prolongation and complex ventricular arrhythmia. The drug was discontinued. Over the subsequent 36-hours, the patient remained in sinus rhythm except for one brief run of ventricular bigeminy. An ECG recorded 5 months after admission (and about 4 months after cessation of all QT-prolonging medications) showed sinus rhythm with normal heart rate and corrected QT interval.

QT prolongation and torsade de pointes have also been reported during postmarketing experience.[Ref]


Uncommon (0.1% to 1%): Anemia

Rare (less than 0.1%): Leukopenia, neutropenia, agranulocytosis, thrombocytopenia

Frequency not reported: Eosinophilia[Ref]

Anemia, eosinophilia, leukopenia, neutropenia, and thrombocytopenia have been reported, often in patients with severe deep fungal infections or underlying disease.

Spontaneous reports of anemia were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of anemia in the elderly. A causal relationship to drug exposure could not be determined.

Anemia, leukopenia, neutropenia, agranulocytosis, and thrombocytopenia have also been reported during postmarketing experience.[Ref]


Fever, asthenia, fatigue, and malaise have also been reported during postmarketing experience.[Ref]

Uncommon (0.1% to 1%): Thirst, fatigue, malaise, pain, rigors, asthenia, fever, flushing, hot flushes

Rare (less than 0.1%): Face edema

Frequency not reported: Infection due to resistant microorganisms[Ref]


Uncommon (0.1% to 1%): Back pain, myalgia

Frequency not reported: Joint pain, finger stiffness[Ref]

Myalgia has also been reported during postmarketing experience.[Ref]


Insomnia has also been reported during postmarketing experience.

Uncommon (0.1% to 1%): Insomnia, nervousness


Uncommon (0.1% to 1%): Polyuria, renal pain, changes in renal function tests

Frequency not reported: Membranous nephropathy

Postmarketing reports: Acute renal failure[Ref]

A 58-year-old female with a history of hypertension and cervical cancer experienced membranous nephropathy coincident with this drug. The patient presented with increasing generalized edema accompanied by nausea and indigestion for 3 weeks. Clinical findings showed the patient had stage I membranous nephropathy. At initial presentation, the patient's medication history included amlodipine, hydrochlorothiazide, metoclopramide, and levosulpiride. She did not admit to taking fluconazole. Five months after the initial presentation, the patient returned with reports of increasing pedal edema. At that point, the patient admitted to taking this drug once a week for tinea pedis. The patient went into complete remission when the drug was stopped.

Spontaneous reports of acute renal failure were more frequent in patients 65 years of age or older than in those between 12 and 65 years of age; however, there is a natural increase in the incidence of renal failure in the elderly. A causal relationship to drug exposure could not be determined.[Ref]


Uncommon (0.1% to 1%): Intermenstrual bleeding, dysmenorrhea, leukorrhea, menorrhagia, uterine spasm, vaginal disorders, female sexual dysfunction


Uncommon (0.1% to 1%): Pharyngitis

Frequency not reported: Respiratory disorders[Ref]


Uncommon (0.1% to 1%): Abnormal vision

Frequently asked questions


1. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990;39:877-916.

2. Product Information. Diflucan (fluconazole). Roerig Division. 2001;PROD.

3. Cerner Multum, Inc. UK Summary of Product Characteristics.

4. Cerner Multum, Inc. Australian Product Information.

5. Phillips RJ, Watson SA, McKay FF. An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. Br J Clin Pract. 1990;44:219-22.

6. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med. 1992;326:83-9.

7. Robinson PA, Knirsch AK, Joseph JA. Fluconazole for life-threatening fungal infections in patients who cannot be treated with conventional antifungal agents. Rev Infect Dis. 1990;12:s349-63.

8. Inman W, Pearce G, Wilton L. Safety of fluconazole in the treatment of vaginal candidiasis - a prescription-event monitoring study, with special reference to the outcome of pregnancy. Eur J Clin Pharmacol. 1994;46:115-8.

9. Gupta AK, Ryder JE. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin. 2003;21:469-79, vi.

10. Thompson GR 3rd, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med. 2009;30:203-15, v.

11. Ikemoto H. A clinical study of fluconazole for the treatment of deep mycoses. Diagn Microbiol Infect Dis. 1989;12:s239-47.

12. De Wit S, Clumeck N. Fluconazole in the treatment of fungal infections associated with AIDS. Infection. 1989;17:121-3.

13. Vincent-Ballereau FN, Patey ON, Lafaix C. Fluconazole: review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections. Pharm Weekbl Sci. 1990;13:45-57.

14. Holechek MJ. Medication review: fluconazole. ANNA J. 1991;18:585-6.

15. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:580-4.

16. Morrow JD. Fluconazole: a new triazole antifungal agent. Am J Med Sci. 1991;302:129-32.

17. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845-51.

18. Franklin IM, Elias E, Hirsch C. Fluconazole-induced jaundice. Lancet. 1990;336:565.

19. Munoz P, Moreno S, Berenguer J, et al. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1991;151:1020-1.

20. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS. 1992;6:191-4.

21. Wells C, Lever AM. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge . J Infect. 1992;24:111-2.

22. Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med. 1994;96:188-90.

23. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother. 1994;28:1177-81.

24. Guillaume MP, Deprez C, Cogan E. Subacute mitochondrial liver disease in a patient with AIDS: possible relationship to prolonged fluconazole administration. Am J Gastroenterol. 1996;91:165-8.

25. Pappas PG, Kauffman CA, Perfect J, Johnson PC, Mckinsey DS, Bamberger DM, Hamill R, Sharkey PK, Chapman SW, Sobel JD. Alopecia associated with fluconazole therapy. Ann Intern Med. 1995;123:354-7.

26. Goldsmith LA. Alopecia associated with fluconazole therapy. Ann Intern Med. 1996;125:153.

27. Shear NH. Alopecia associated with fluconazole therapy. Ann Intern Med. 1996;125:153.

28. Craig TJ, Peralta F, Boggavarapu J. Desensitization for fluconazole hypersensitivity. J Allergy Clin Immunol. 1996;98:845-6.

29. Abbott M, Hughes DL, Patel R, Kinghorn GR. Angio-oedema after fluconazole. Lancet. 1991;338:633.

30. Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van Wout JW. Stevens-Johnson syndrome after fluconazole. Lancet. 1991;338:120.

31. Neuhaus G, Pavic N, Pletscher M. Anaphylactic reaction after oral fluconazole. Br Med J. 1991;302:1341.

32. Gupta R, Thami GP. Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity. J Am Acad Dermatol. 2008;58:521-522.

33. Beecker J, Colantonio S. Fixed drug eruption due to fluconazole. CMAJ. 2012;184:675.

34. Esch JJ, Kantoch MJ. Torsades de pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Pediatr Cardiol. 2007;29:210-3.

35. McMahon JH, Grayson ML. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. Am J Health Syst Pharm. 2008;65:619-23.

36. Agarwal A, Sakhuja V, Chugh KS. Fluconazole-induced thrombocytopenia. Ann Intern Med. 1990;113:899.

37. Mercurio MG, Elewski BE. Thrombocytopenia caused by fluconazole therapy. J Am Acad Dermatol. 1995;32:525-6.

38. Pappas PG, Kauffman CA, Sobel JD. Alopecia associated with fluconazole therapy. Ann Intern Med. 1996;125:153-4.

39. Kalivas J. Thrombocytopenia caused by fluconazole. J Am Acad Dermatol. 1996;35:284.

40. Mercurio MG, Elewski BE. Thrombocytopenia caused by fluconazole - reply. J Am Acad Dermatol. 1996;35:284.

41. Shin GT, Yim H, Park J, Kim H. Membranous nephropathy associated with fluconazole treatment. Am J Kidney Dis. 2007;49:318-22.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.